|
Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut neuroendocrine tumors. |
|
|
|
Consulting or Advisory Role - Ipsen; Lexicon; Novartis |
Speakers' Bureau - Ipsen; Lexicon |
Research Funding - Novartis; Pharmacyclics |
Travel, Accommodations, Expenses - Advanced Accelerator Applications |
|
|
Consulting or Advisory Role - Advanced Accelerator Applications; Ipsen; Lexicon; Novartis |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Ipsen; Lexicon; Novartis |
|
|
|
Research Funding - Advanced Accelerator Applications |
|
|
Honoraria - Advanced Accelerator Applications |
Consulting or Advisory Role - Advanced Accelerator Applications |
|
|
Stock and Other Ownership Interests - Advanced Accelerator Applications (I); Endocyte (I) |
Consulting or Advisory Role - Isotopen Technologien |
Research Funding - Advanced Accelerator Applications (Inst) |
|
|
Consulting or Advisory Role - Abbvie |
Research Funding - Novartis (Inst) |
|
|
Consulting or Advisory Role - Ipsen; Novartis; Perthera |
Travel, Accommodations, Expenses - Halozyme |
|
|
No Relationships to Disclose |
|
|
Employment - Advanced Accelerator Applications |
|
|
Employment - Advanced Accelerator Applications |
|
|
No Relationships to Disclose |
|
|
Honoraria - Advanced Accelerator Applications |
Consulting or Advisory Role - Advanced Accelerator Applications |
|
|
Employment - Advanced Accelerator Applications |
|
|
Consulting or Advisory Role - Advanced Accelerator Applications |
Travel, Accommodations, Expenses - Advanced Accelerator Applications |